药学学报
藥學學報
약학학보
ACTA PHARMACEUTICA SINICA
2001年
2期
131-133
,共3页
马来酸曲美布汀%高效毛细管电泳法%药物动力学
馬來痠麯美佈汀%高效毛細管電泳法%藥物動力學
마래산곡미포정%고효모세관전영법%약물동역학
目的 建立快速、准确测定大鼠血浆中马来酸曲美布汀浓度的HPCE方法，并用于其在大鼠体内的药物动力学研究。方法 以盐酸麻黄碱为内标，0.03 mol*L-1磷酸二氢钠(pH 6.0)为运行缓冲溶液，紫外检测波长为214 nm。血浆样品经乙腈除蛋白后，于50℃水浴用氮气吹干，残渣溶于甲醇-水(1∶1)，进样分析。结果 线性范围5-200 μg*L-1，日内RSD<14%，日间RSD<13%，回收率为72.8%-87.9%，最低定量浓度为5 μg*L-1。ig给药30 min后，血浆中药物浓度达峰值，T1/2(Ke)为173 min，Ke为5.6×10-3 min-1，AUC为7.83 μg*min*mL-1。结论 方法灵敏度高，操作简便，适用于马来酸曲美布汀的药物动力学研究。
目的 建立快速、準確測定大鼠血漿中馬來痠麯美佈汀濃度的HPCE方法，併用于其在大鼠體內的藥物動力學研究。方法 以鹽痠痳黃堿為內標，0.03 mol*L-1燐痠二氫鈉(pH 6.0)為運行緩遲溶液，紫外檢測波長為214 nm。血漿樣品經乙腈除蛋白後，于50℃水浴用氮氣吹榦，殘渣溶于甲醇-水(1∶1)，進樣分析。結果 線性範圍5-200 μg*L-1，日內RSD<14%，日間RSD<13%，迴收率為72.8%-87.9%，最低定量濃度為5 μg*L-1。ig給藥30 min後，血漿中藥物濃度達峰值，T1/2(Ke)為173 min，Ke為5.6×10-3 min-1，AUC為7.83 μg*min*mL-1。結論 方法靈敏度高，操作簡便，適用于馬來痠麯美佈汀的藥物動力學研究。
목적 건립쾌속、준학측정대서혈장중마래산곡미포정농도적HPCE방법，병용우기재대서체내적약물동역학연구。방법 이염산마황감위내표，0.03 mol*L-1린산이경납(pH 6.0)위운행완충용액，자외검측파장위214 nm。혈장양품경을정제단백후，우50℃수욕용담기취간，잔사용우갑순-수(1∶1)，진양분석。결과 선성범위5-200 μg*L-1，일내RSD<14%，일간RSD<13%，회수솔위72.8%-87.9%，최저정량농도위5 μg*L-1。ig급약30 min후，혈장중약물농도체봉치，T1/2(Ke)위173 min，Ke위5.6×10-3 min-1，AUC위7.83 μg*min*mL-1。결론 방법령민도고，조작간편，괄용우마래산곡미포정적약물동역학연구。
AIM To develop a method for the determination of trimebutine maleate in rat plasma by using high performance capillary electrophoresis. The method was employed to pharmacokinetic analysis of trimebutine maleate. METHODS Plasma samples were deproteinized with acetonitrile (containing ephedrine hydrochloride as internal standard) and the supernatant was dried under N2 stream at 50℃. The residue was dissolved with methanol-water (1∶1) and injected into the capillary by siphon. The electrophoresis was performed in uncoated fused-silica capillary and the voltage was 10 kV. The running buffer was 0.03 mol*L-1 NaH2PO4 (pH 6.0). The eluate was detected at 214 nm by UV detection. RESULTS The recovery for trimebutine maleate in rat plasma was 72.8%-87.9%. The calibration curve in plasma was linear over the range 5-200 μg*L-1. The limit of quantitation was 5 μg*L-1. The intraday relative standard deviation (n=6) and the interday relative standard deviation (n=18) were less than 14%. The highest concentration in plasma was observed at 30 min after ig trimebutine maleate to rats. The pharmacokinetic results were AUC0-∞=8 μg*min*mL-1, T1/2(Ke)=173 min and Ke=5.6×10-3 min-1. CONCLUSION The method is accurate, sensitive and suitable for pharmacokinetic study of trimebutine maleate.
